Cantor Fitzgerald Upgrades Astria Therapeutics (NASDAQ:ATXS) to Strong-Buy
Cantor Fitzgerald upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2025 earnings at ($1.98) EPS. Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a […]
Cantor Fitzgerald upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2025 earnings at ($1.98) EPS. Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a […]
